Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) EBITDA Margin (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of EBITDA Margin data on record, last reported at 14518.37% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 737211.0% year-over-year to 14518.37%; the TTM value through Sep 2025 reached 6738.3%, down 337165.0%, while the annual FY2024 figure was 2967.56%, 948041.0% up from the prior year.
  • EBITDA Margin reached 14518.37% in Q3 2025 per BTAI's latest filing, down from 13210.0% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 449714.29% in Q1 2022 and bottomed at 24853.4% in Q1 2023.
  • Average EBITDA Margin over 4 years is 21717.88%, with a median of 6011.31% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: plummeted -47456768bps in 2023, then surged 2070168bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 22224.37% in 2022, then surged by 76bps to 5285.37% in 2023, then skyrocketed by 46bps to 2866.94% in 2024, then tumbled by -406bps to 14518.37% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 14518.37% in Q3 2025, 13210.0% in Q2 2025, and 6011.31% in Q1 2025.